Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$144.44 USD

144.44
8,262,712

+0.06 (0.04%)

Updated May 29, 2024 04:00 PM ET

After-Market: $144.51 +0.07 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for JNJ

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Johnson & Johnson [JNJ]

Reports for Purchase

Showing records 481 - 499 ( 499 total )

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 481

01/25/2011

Company Report

Pages: 9

4Q EPS Met Expectations

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 482

01/21/2011

Company Report

Pages: 12

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 483

11/01/2010

Company Report

Pages: 14

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 484

10/21/2010

Company Report

Pages: 13

Potential resolution of McNeil recall/OTC issues & successful execution of new product

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 485

10/20/2010

Company Report

Pages: 2

Expect improvement after Q3 pressure

Provider: G.RESEARCH, LLC

Analyst: JONAS J

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 486

10/19/2010

Company Report

Pages: 9

Non-operating Factors Helped Beat Estimates.

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 487

08/17/2010

Industry Report

Pages: 13

MEDTECH TECHNICAL PAIR TRADE IDEAS

Provider: CAPSTONE INVESTMENTS

Analyst: SINE B

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 488

08/05/2010

Company Report

Pages: 12

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 489

07/23/2010

Company Report

Pages: 13

CY10 to be a challenging period but potential resolution of McNeil recall/OTC issues & successful execution of new product launches to help resume growth momentum from FY11 onwards.

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 490

07/21/2010

Company Report

Pages: 2

Q2 results show new challenges

Provider: G.RESEARCH, LLC

Analyst: JONAS J

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 491

07/20/2010

Company Report

Pages: 8

Second Quarter Results Impacted by Consumer Recalls and Conditions in Europe

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 492

05/04/2010

Company Report

Pages: 11

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 493

04/21/2010

Company Report

Pages: 2

Acceleration starts here

Provider: G.RESEARCH, LLC

Analyst: JONAS J

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 494

04/20/2010

Company Report

Pages: 9

1Q EPS Ahead of Expectations Despite Product Recalls, Generics, and Health Care Changes

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 495

02/22/2010

Industry Report

Pages: 37

Biotech Balance Sheet

Provider: Merriman Curhan Ford & Co.

Price: 75.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 496

02/03/2010

Company Report

Pages: 10

Price: 24.95

Company: Johnson & Johnson

Industry: Medical - Drugs

Record: 497

01/29/2010

Company Report

Pages: 14

Topline growth to bounce back in CY10, led by diverse revenue stream, restructuring initiatives & slew of new product launches ahead

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Medical - Drugs

Record: 498

01/27/2010

Company Report

Pages: 2

Strong finish to a Challenging 2009

Provider: G.RESEARCH, LLC

Analyst: JONAS J

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Medical - Drugs

Record: 499

01/27/2010

Company Report

Pages: 9

Fourth Quarter Revenue Benefited from Positive Currency Effects. EPS Better Than Expected.

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party